Tolerogenic dendritic cells: promising cell therapy for acute kidney injury.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37599014.
- Also identified by DOI 10.1016/j.kint.2023.06.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is still no established treatment for acute kidney injury (AKI), and the intervention of AKI remains limited to supportive treatments. Li et al. demonstrated the mechanism by which immune tolerance by dendritic cell ameliorates AKI in a mouse ischemia-reperfusion injury model. The phase I/II clinical trials of tolerogenic dendritic cell therapy have been conducted for kidney transplantation, so it is expected to have potential as a cell therapy for AKI in the future.
Medical subject headings
- Acute Kidney Injury
- Kidney Transplantation